There is a high demand for safe and long-lasting medications to treat bone loss, known medically as osteoporosis. In Germany, around six million people – mostly women – are affected by this widespread condition. Discovering new targets for drug development is therefore a key step towards better therapies with fewer side effects. The adhesion G protein-coupled receptor GPR133 belongs to a still relatively unexplored group of receptors. In a recent study, scientists at Leipzig University…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply